Molecular and Functional Insights into the ADIPOR1 Gene in Metabolic Regulation

Abstract

The adiponectin receptor 1 (ADIPOR1) gene encodes a transmembrane protein that plays a pivotal role in maintaining metabolic homeostasis. ADIPOR1 primarily mediates the biological effects of adiponectin, an adipokine involved in regulating glucose uptake, fatty acid oxidation, insulin sensitivity, and energy balance. The receptor is highly expressed in skeletal muscle and various metabolically active tissues, where it activates key signaling pathways such as AMP-activated protein kinase (AMPK) and peroxisome proliferator-activated receptor-α (PPAR-α). Through these pathways, ADIPOR1 contributes to improved insulin responsiveness and reduced lipid accumulation. Genetic variations in the ADIPOR1 gene have been increasingly associated with metabolic disorders including obesity, type 2 diabetes mellitus, insulin resistance, and cardiovascular complications. Non-synonymous single nucleotide polymorphisms (nsSNPs) within ADIPOR1 may alter protein conformation, stability, or receptor–ligand interactions, thereby impairing downstream signaling. Advances in computational biology have enabled the identification and functional prediction of potentially deleterious ADIPOR1 variants using in silico tools that assess evolutionary conservation, pathogenicity, and structural impact. Structural studies indicate that ADIPOR1 possesses a unique seven-transmembrane domain architecture distinct from classical G-protein-coupled receptors, suggesting specialized signaling mechanisms. Disruption of conserved residues within these domains can significantly affect receptor activity and metabolic signaling efficiency. Moreover, pharmacological agonists such as AdipoRON have highlighted ADIPOR1 as a promising therapeutic target for metabolic diseases. Overall, the ADIPOR1 gene represents a critical molecular link between adipokine signaling and metabolic regulation. Continued exploration of its genetic variants and molecular mechanisms may provide valuable insights for precision medicine approaches and the development of targeted therapies for metabolic disorders.